InnoCan Pharma (INNO) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 surged 177% year-over-year to $8.6 million, driven by strong sales from the BI Sky Global subsidiary.

• Net profit reached $0.95 million, reversing a net loss of $0.4 million in Q2 2023.

• Management highlighted advancements in LPT-CBD technology and ongoing FDA discussions for chronic pain clinical plans.

Financial highlights

• Q2 2024 revenue was $8.6 million, up from $3.1 million in Q2 2023 and $6.8 million in Q1 2024.

• Gross profit increased 201% year-over-year to $8.0 million, up 33% sequentially.

• Operating profit improved to $0.53 million from a loss of $0.44 million in Q2 2023.

• Net profit improved by $1.35 million year-over-year and $2.4 million sequentially.

Outlook and guidance

• Management expects continued accelerated growth with new product categories and innovative formulations.

• Awaiting FDA feedback on LPT-CBD technology for chronic pain, with optimism for future milestones.